Larry BenedictFounder, The Opportunistic Trader

Larry Benedict

Larry Benedict is a 35-year trading veteran. Starting from the pits at the Chicago Board Options Exchange (CBOE), Larry’s skills grew until he was running a world-class $800 million hedge fund – where he regularly traded position sizes in the millions of dollars. He even went 20 years without a single losing year… putting his hedge fund in the top 1% of Barron’s rankings.

That’s because, from 1990 through 2010, Larry’s hedge fund never had a single losing year. (It wasn’t until 2011 that he had a losing year, and even then, the fund was down less than 1%.) In 2008, when the financial world was in upheaval, Larry and his partners had their best year ever, making $95 million for their clients.

Now though, Larry fully devotes himself to bringing his trading secrets to everyday investors – with actionable, profitable options plays and other top-level strategies that made him a massive success.

Larry Benedict’s Research Services

Trading With Larry Benedict

Learn more

The Opportunistic Trader

Learn more

The S&P Trader

Learn more

One Ticker Trader

Learn more

Currency Wizard

Learn more

Larry Benedict 360

Learn more

How Being Nimble Generated a 94% Return in a Week

Traders must be ready to take any profits off the table and prepare for the next trade...

Even the Hedge Funds Have This Market All Wrong

Since the Fed waited too long, it’s now playing a massive game of catch up...

After a Sharp 50% Rally, Is Tesla’s Next Move Down?

These kinds of big moves in TSLA are not uncommon...

Why Higher Inflation Equals More Opportunity

Prices for most major commodities have gone through the roof...

Why Wheat Can Continue to Fall

All six of the major food groups tracked in the CPI data saw rises across the board...

This Trend in Home Construction Isn’t Over

Home construction has a multiplier effect across the economy...

How Home Prices Can Affect the Stock Market

Several factors helped push home prices higher...

The Struggles Could Be Over for This Sector

Some biotech stocks moved higher from COVID research funding, while others suffered...